| Autor: |
Schlömicher, M., Haldenwang, P., Berres, D., Moustafine, V., Bechtel, M., Strauch, J. |
| Předmět: |
|
| Zdroj: |
Thoracic & Cardiovascular Surgeon; 2024 Supplement1, Vol. 72, pS1-S68, 68p |
| Abstrakt: |
This article discusses the outcomes of implanting a new generation biological valve with a novel anticalcification treatment. The study included 110 patients who underwent aortic valve replacement using this valve between December 2018 and January 2022. The results showed low rates of mortality, stroke, and major paravalvular leaks. The valve demonstrated excellent safety and hemodynamic performance, with minimal regurgitation and no evidence of structural valve deterioration. The study suggests that this latest generation bioprosthesis is a promising option for patients in need of aortic valve replacement. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
